Skip to content
Lower risk Drug recall · FDA · Published May 3, 2021

Pfizer 0.5% Bupivacaine Vials May Contain Wrong Medication

Pfizer recalls 30mL single-dose vials of 0.5% Bupivacaine Hydrochloride Injection that may contain lidocaine instead. This labeling mix-up could lead to incorrect medication use during medical procedures.

🇺🇸 FDA recall #D-0626-2021DrugPfizer ›
Take action

Contact the company

Recalling firmPFIZER, INC275 N Field Dr Bldg H3-3N · Lake Forest, IL 60045-2579
✎ GovInfoNow plain-language explainer

Pfizer is recalling 30mL single-dose vials of 0.5% Bupivacaine Hydrochloride Injection due to a labeling mix-up. Some vials labeled as containing bupivacaine may actually contain lidocaine, and vice versa. This could lead to incorrect medication administration during medical procedures. Read more at govinfonow.com/recall/36159-pfizer-0-5-bupivacaine-vials-may-contain-wrong-medication.

Source Summary by GovInfoNow · govinfonow.com/recall/36159-pfizer-0-5-bupivacaine-vials-may-contain-wrong-medication · Updated October 4, 2026 · FDA enforcement record: FDA #D-0626-2021

Cite this page

“Pfizer 0.5% Bupivacaine Vials May Contain Wrong Medication.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36159-pfizer-0-5-bupivacaine-vials-may-contain-wrong-medication. Based on FDA recall #D-0626-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0626-2021%22&limit=1).

Pfizer, Inc. recalled 0.5% Bupivacaine Hydrochloride Injection vials due to a labeling mix-up that may cause the wrong drug to be administered, according to the FDA on May 3, 2021.

How to tell if you have it

  • Brand: Pfizer
  • Product: 0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19)
  • Packaging: 25 vials per tray (NDC 0409-1162-02)
  • Lot code: EG6023
  • Expiration date: 07/01/2022
  • Units affected: 163,957 vials

The hazard

Some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP.

Context

GovInfoNow's records show Pfizer Inc. has 71 other recalls on record since November 26, 2012. Other recent recalls of similar products include Pfizer Epinephrine Vial Recall (August 4, 2025), Pfizer Bicillin L-A Injectable Suspension Recall (July 10, 2025), and Pfizer recalls DOBUTamine injection vials with discoloration risk (May 28, 2025). Other recent recalls of similar products include American Health Packaging Buprenorphine Tablets Recall (August 19, 2026), Pfizer Dopamine HCl Inj Recall (September 4, 2026), and American Regent Levocarnitine Injection Recall (April 16, 2026).

How to tell if you have this one

Check for vials labeled as '0.5% Bupivacaine Hydrochloride Injection, USP' that may contain lidocaine. The vials have NDC 0409-1162-19 and were packaged in 25 per tray (NDC 0409-1162-02).

  • Brand
    Pfizer
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class I
  • Status
    Terminated
  • Distribution
    Nationwide in the USA, Puerto Rico, and Guam
Recall numberProduct, codes & lotsQuantityNDC
D-0626-20210.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.; Lot EG6023, Exp. 07/01/2022163,957 vials0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17
D-0627-20211% Lidocaine HCl Injection, USP, 300 mg/30 mL (10 mg/mL), 30 mL Single-dose vial (NDC 0409-4279-16), packaged in 25 vials per tray (NDC 0409-4279-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.; Lot EG8933, Exp. 08/01/2022139,050 vials0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01
Based on the official FDA remedy

What to do — step by step

  1. Check Vial Label

    Verify the label on the vial to ensure it matches the intended medication. If the label shows 0.5% Bupivacaine Hydrochloride Injection, USP, it may contain lidocaine instead.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the USA, Puerto Rico, and Guam” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 23 months after the firm started it.

1. Firm started the recall: May 3, 202112. Published in FDA’s Enforcement Report: Jun 9, 202123. FDA classified it Class I: Jun 10, 202134. FDA terminated the recall: Apr 4, 2023420212023
  1. Firm started the recall
  2. Published in FDA’s Enforcement Report
  3. FDA classified it Class I
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0626-2021 (May 3, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0626-2021 to see it in context.
  • Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA